Terapia hormonal de reemplazo y cáncer

  • Gilberto Martínez Morales

Resumen

El temor al riesgo de algunos tipos de cáncer, en especial el mamario relacionado con el uso de la terapia hormonal de reemplazo, a lo largo de las últimas tres décadas ha sido un tema de controversia e investigación permanente. Al comienzo del nuevo milenio la información publicada ha permitido obtener más claridad en la materia aunque no toda la que se quisiera a pesar de las nuevas metodologías utilizadas en la investigación; sin embargo, creemos que estamos lejos de conocer la verdad. Pero probablemente más que los mismos resultados, en muchos casos es la interpretación y difusión que se le da a los mismos lo que más impacta en la toma de decisiones en la práctica médica. Diferencias poblacionales, raciales y geográficas entre otras, han mostrado grandes desigualdades en relación con el riesgo de padecer un determinado cáncer, así como las barreras económicas han limitado también la exposición a noxas cancerígenas. El papel de las combinaciones de estrógenos más progesterona y el de los estrógenos equinos conjugados está ahora más definido en relación con la carcinogénesis, pero no así el relacionado con la información sobre las nuevas moléculas, las dosis bajas y las diferentes vías de administración que ya se están utilizando. El médico deberá acudir cada vez más a las herramientas que le facilita la epidemiología para comprender mejor la información y trasmitirla a sus pacientes y los sistemas de salud deberán facilitarle a ambos los espacios suficientes para una sana decisión.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Gilberto Martínez Morales
Ginecólogo-Oncólogo, Jefe Sección de Ginecología Oncológica, Fundación Santa Fe de Bogotá, Bogotá, Colombia.

Referencias bibliográficas

Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344;276-85.

Cosman F, Lindsay R. Selective estrogen receptors modulators: clinical spectrum. Endocr Rev 1999;20:418-34.

Santen RJ, Leszczynski D, Tilson-Mallet N, Feil PD, Wright C, Manni A, et al. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfate pathways. Ann NY Acad Sci 1986;464:126-37.

Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp 19) and breast cancer risk. Br J Cancer 1999;79: 456-63.

Khan SA, Rogers MA, Obando JA, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994;54:993-7.

Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.

Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.

Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992;79:286-94.

Colditz GA, Hankinson SE, Hunter DJ Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.

Dupont WD, Page DL, Parl FF, Plummer WD Jr, Schuyler PA, Kasami M, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 1999;85:1277-83.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart And Estrogen/ Progestin Replacement Study (HERS) Research Group. JAMA 1998:605-13.

Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6,8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II) JAMA 2002;288:49-57.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biological prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-7.

Squitieri R, Tartter PI, Ahmed S, Brower ST, Theise ND. Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 1994;178:167-70.

Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999;281:2091-7.

Cobleigh MA, Norlock FE, Oleske DM, Starr A. Hormone replacement therapy and high S phase in breast cancer. JAMA 1999;281:1528-30.

DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174:1494-8.

Loprinzi CL, Sloan JA, Perez EA, et al. Fluoxetine reduces hot flashes. Program and abstracts of the 37 Annual Meeting of the American Society of Clinical Oncology, May 12-15, 2001; San Francisco, California, Abstract 199.

Jacobson JS, Grann VR, Troxel AB, et al. Randomized trial of an herbal remedy for hot flashes among women with breast cancer. Program and abstracts of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12-15, 2001; San Francisco, California. Abstract 1593.

Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85-92.

Tice JA, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA 2003;290:207-14.

Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357-63.

Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 2002;95(9):1817-26.

Santen R, Pritchard K, Burger H. The consensus conference on treatment of estrogen deficiency symptoms in women surviving breast cancer. Obstet Gynecol Surv 1998;53(10 Suppl):S1-83.

Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.

Mack TM, Pike MC, Henderson BE, Pfeffer RI, Gerkins VR, Arthur M, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med 1976;294:1262-7.

The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;370-5.

Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.

Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979:54:74-9.

Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol.1986;67:326-30.

Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-91.

Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-200.

Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001;97:555-60

The Cancer and Steroid Hormone Study of the Centres for Disease Control and National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med 1987;316:650-5

Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-alfha, and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc. Natl Acad Sci USA 1999;96:5722-7.

Mercuri N, Petraglia F, Genazzani AD, Amato F, Sgherzi MR, Maietta-Latessa A, et al. Hormonal treatments modulate pulsatile plasma growth hormone, gonadotrophin and osteocalcin levels in postmenopausal women. Maturitas 1993;17:51-62.

Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W, Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996;62:4-6.

Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-75.

Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analisys. Obstet Gynecol 1998;92:472-9.

Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US woman. JAMA 2001;285:1460-5.

Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.

Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999;81(3):559-63.

Eeles RA, Tan S, Wiltshaaw E, Fryatt I, A'Hern RP, Shepherd JH, et al. Hormonal replacement therapy and survival alter surgery for ovarian cancer. BMJ 1991;302:259-62.

Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors. Cancer 1999;86:1013-8.

Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995;87:1039-40.

Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and the risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517-23.

English MA, Stewart PM, Hewison M. Estrogen metabolism and malignancy: analysis of the expression and function of 17beta-hydroxysteroids dehydrogenases in colonic cancer. Mol Cell Endocrinol 2001;171:53-60.

Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.

Wu-Williams AH, Lee M, Whittemore AS, Gallagher RP, Jiao DA, Zheng S, et al. Reproductive factors and colorectal cancer risk among Chinese females. Cancer Res 1991;51:2307-11.

Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after five years. Arch Intern Med 1994;154:2585-8.

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.

Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-57.

Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2,5 mg daily; effects on bone loss in postmenopausal women. Climacteric 2002;5:390-8.

Kloosterboer HJ, Ederveen AGH. Pros and cons existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments. J Steroid Biochem Mol Biol 2002;83:157-65.

Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet 2003;362:419-27.

Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT Study. Foxamax International Trial Study Group. Osteoporos Int 1999;9:461-8.

Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.

Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, et al. A Meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2000;12:140-51.

Reid I, Brown J, Burkhard P, et al. Intravenous Zoledronic Acid in Postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.

Newton K, Buist D, Keenan N, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol 2002;100:18-25.

Tice J, Ettinger B, Ensrud K, Wallace R, Blackwell T, Cummings SR. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study. JAMA 2003;290:207-14.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41.

Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et al; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552-9.

Ganz PA. Menopause and breast cancer: symptoms, late effects and their management. Semin Oncol 2001;28:274-83.

Publicado
2004-03-30
Cómo citar
1.
Martínez Morales G. Terapia hormonal de reemplazo y cáncer. Rev. Colomb. Obstet. Ginecol. [Internet]. 30 de marzo de 2004 [citado 17 de enero de 2022];55(1):40-9. Disponible en: https://revista.fecolsog.org/index.php/rcog/article/view/611
Sección
Artículo de Revisión
Crossref Cited-by logo